MARIO RODRIGUES LOUZA NETO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
40 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 40
bookPart Tratamento da esquizofrenia(2021) LOUZã, Mário Rodrigues; KAYO, Monica; VIZZOTTO, Adriana Dias Barbosa; MELZER-RIBEIRO, Débora Luciana; SARNO, Elaine Scapaticio Di; OLIVEIRA, Graça Maria Ramos de; NAPOLITANO, Isabel Cristina; GOMES, Mônica Lopes; ELKIS, HelioconferenceObject COMPARISON OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FACTOR STRUCTURE IN PATIENTS WITH REFRACTORY VERSUS NON REFRACTORY SCHIZOPHRENIA(2015) FREITAS, Rosana Ramos; VIZZOTTO, Adriana Dias Barbosa; AVRICHIR, Belquiz; SCENES, Silvia; SA JUNIOR, Antonio Reis de; SANTOS, Bernardo Pereira; LOUZA NETO, Mario Rodrigues; ELKIS, HeliobookPart Transtorno de déficit de atenção/hiperatividade(2015) ANDRADE, Ênio Roberto de; LOUZã NETO, MariobookPart Ansiedade(2015) LOUZã NETO, Mario Rodrigues- THE KUMON METHOD FOR COGNITIVE REMEDIATION OF INDIVIDUALS WITH SCHIZOPHRENIA: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL(2014) CRIVELARO, Marisa M.; MARTINS, Paula; MUSSKOPFT, Monia; AYUSO, Suely; ARCURY, Silvia; MARTINS, Paula; CELIDONIO, Zilda; BERTINHO, Rosa; LOUZA, Mario
bookPart Sintomas Físicos Inexplicáveis(2015) LOUZã NETO, Mario Rodrigues- ANDES NETWORK - STUDYING EARLY PSYCHOSIS IN LATIN AMERICA(2019) CROSSLEY, Nicolas; GUINJOAN, Salvador; RIVERA, Guillermo; JACKOWSKI, Andrea; GADELHA, Ary; ELKIS, Helio; LOUZA, Mario; GAMA, Clarissa; EVANS-LACKO, Sara; CASTANEDA, Carmen Paz; UNDURRAGA, Eduardo; CORDOBA, Rodrigo; LOPEZ-JARAMILLO, Carlos; FUENTE-SANDOVAL, Camilo de la; BRESSAN, Rodrigo
- Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification(2021) ROSA, Pedro Gomes Penteado; ZUGMAN, Andre; CERQUEIRA, Carlos Toledo; SERPA, Mauricio Henriques; DURAN, Fabio Luis de Souza; ZANETTI, Marcus Vinicius; BASSITT, Debora Pastore; ELKIS, Helio; CRIPPA, Jose Alexandre S.; SALLET, Paulo Clemente; GATTAZ, Wagner Farid; HALLAK, Jaime Eduardo Cecilio; LOUZA, Mario Rodrigues; GADELHA, Ary; JACKOWSKI, Andrea Parolin; BRESSAN, Rodrigo Affonseca; BUSATTO FILHO, GeraldoBackground: Brain magnetic resonance imaging studies have not investigated the cortical surface comprehensively in schizophrenia subjects by assessing thickness, surface area and gyrification separately during the first episode of psychosis (FEP) or chronic schizophrenia (ChSch). Methods: We investigated cortical surface abnormalities in 137 FEP patients and 240 ChSch subjects compared to 297 Healthy Controls (HC) contributed by five cohorts. Maps showing results of vertexwise between-group comparisons of cortical thickness, area, and gyrification were produced using T1-weighted datasets processed using FreeSurfer 5.3, followed by validated quality control protocols. Results: FEP subjects showed large clusters of increased area and gyrification relative to HC in prefrontal and insuli cortices (Cohen's d: 0.049 to 0.28). These between-group differences occurred partially beyond the effect of sample. ChSch subjects displayed reduced cortical thickness relative to HC in smaller fronto-temporal foci (d:-0.73 to-0.35), but not beyond the effect of sample. Differences between FEP and HC subjects were associated with male gender, younger age, and earlier illness onset, while differences between ChSch and HC were associated with treatment-resistance and first-generation antipsychotic (FGA) intake independently of sample effect. Conclusions: Separate assessments of FEP and ChSch revealed abnormalities that differed in regional distribution, phenotypes affected and effect size. In FEP, associations of greater cortical area and gyrification abnormalities with earlier age of onset suggest an origin on anomalous neurodevelopment, while thickness reductions in ChSch are at least partially explained by treatment-resistance and FGA intake. Associations of between-group differences with clinical variables retained statistical significance beyond the effect of sample.
- A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study(2013) MATTOS, Paulo; LOUZA, Mario Rodrigues; PALMINI, Andre Luis Fernandes; OLIVEIRA, Irismar Reis de; ROCHA, Fabio LopesThe available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD. Objective: To assess the effectiveness of Methyphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. Method: A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted. Results: Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p < .0001), as well as the Total AAQoL (p < .0001). A significant reduction on Clinical Global Impression-Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p < .0001). No serious adverse event was reported. Conclusion: Treatment of adult ADHD patients with OROS MPH improves QoL.
conferenceObject TREATMENT OF CLOZAPINE-INDUCED HYPERSALIVATION WITH AMISULPRIDE: A SYSTEMATIC REVIEW(2014) GRILLI-TISSOT, Maria Cristina R.; LOUZA, M. R.